Original Article

No Association of AS3MT Gene Polymorphisms with Susceptibility to Hepatotoxicity in APL Patients Treated with AS2O3: A Single-Center Study

Abstract

Background: Arsenic three oxide (As2O3) is the treatment choice for acute promyelocytic leukemia (APL). Little is known about possible risk factors with predictive value for toxicity caused by As2O3. Biomethylation is considered to be a major pathway of detoxification for inorganic arsenics (iAs). Arsenic Methyltransferase (AS3MT) is one of the key enzymes involved in the transfer of a methyl group from S-adenosyl-L-methionine to trivalent arsenical and plays a critical role in arsenic detoxification. Polymorphisms in hAS3MT lead to a change in the catalytic activity of the enzyme and may increase the risk of arsenic-related toxicity. In this study, we investigated the association of the AS3MT polymorphisms (rs11191439, rs3740390, and rs3740393) genes with hepatotoxicity in APL patients treated with As2O3.

Materials and Methods: Genotyping was performed in 140 adult patients with APL treated with As2O3 using PCR-RFLP for rs11191439 and tetra-primer ARMS-PCR for rs3740390 and rs3740393. The results of PCR-RFLP and ARMS-PCR were confirmed by direct sequencing of 10 % of DNA samples. The results were analyzed using SNPStats, SPSS, and FinchTV. Hepatotoxicity was graded according to the National Cancer Institute's Common Toxicity Criteria (CTC).
Results: Hepatotoxicity was seen in 52 of the 140 patients (37.1%), with grades I and II hepatotoxicity in 40 (28.6%) and grades III and IV hepatotoxicity in 12 (8.5%) patients.  The association between the three polymorphisms and hepatotoxicity was evaluated using five genetic models and none of the three studied polymorphisms were significantly associated with hepatotoxicity.
Discussion: The results of our study showed that AS3MT rs11191439, rs3740390, and rs3740393 polymorphisms are not associated with hepatotoxicity in APL patients. Genetic polymorphisms in enzymes which are involved in arsenic metabolism have been shown to have ethnicity and race-related differences. To more precisely characterize the association between AS3MT gene polymorphism and hepatotoxicity, future large-scale studies in non-Asian populations and other ethnicities are needed.

1. Cao X, Wen Z, Sun Y, et al. Prognostic value of ABO blood group in patients with surgically resected colon cancer. Br J Cancer. 2014;111(1):174-80.
2. Wei J, Zhang Y, Zheng J, et al. Prognostic value of ABO blood group in a Chinese population in Northwest China region with curatively resected rectal cancer. J Cancer. 2019;10(26):6584-6593.
3. Kashfi SM, Bazrafshan MR, Kashfi SH, et al. The relationship between blood group and colon cancer in Shiraz Namazi Hospital During 2002-2011. Jundishapur Journal of Chronic Disease Care. 2018;7(1):
4. Hsiao LT, Liu NJ, You SL, et al. ABO blood group and the risk of cancer among middle‐aged people in Taiwan. Asia Pac J Clin Oncol. 2015;11(4):e31-6.
5. Celić D, Lipozenčić J, Kolarić B, et al. Association between blood group and nonmelanoma skin cancers (Basal Cell Carcinoma and Squamous Cell Carcinoma). Int J Environ Res Public Health. 2019;16(13):2267.
6. Fotra R, Gupta S, Raina T, et al. Association of ABO and Rh Blood Groups With the Carcinoma of the Cervix With Special Reference to Jammu Region. Biosci Biotechnol Res Asia. 2011;8(1):313-316.
7. Montavon Sartorius C, Schoetzau A, Kettelhack H, et al. ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer. PLoS One. 2018;13(3):e0195213.
8. Saxena S, Chawla VK, Gupta KK, et al. Association of ABO blood group and breast cancer in Jodhpur. Indian J Physiol Pharmacol. 2015;59(1):63-8.
9. Saxena S, Gupta KK. Association of ABO blood groups in relation to gastrointestinal cancers in Jodhpur. Sch J App Med Sci. 2017;5(10C):4013-8.
10. Singh V, Yadav U, Rai V, et al. A Study of Association of ABO Blood Group types with Cancer Risk. bioRxiv. 2019:796284.
11. Tam AA, Özdemir D, Fakı S, et al. ABO Blood Groups, Rh Factor, and Thyroid Cancer Risk: To ‘B’or Not to ‘B’. Endocr Res. 2020;45(2):137-146.
12. Paridar M, Shoushtari MM, Kiani B, et al. Distribution of ABO blood groups and rhesus factor in a Large Scale Study of different cities and ethnicities in Khuzestan province, Iran. Egypt J Med Hum Genet. 2016;17(1):105-9.
13. Kerimov RA, Seksenbaev BD, Galimov OV,et al. The results of the study of blood group and colorectal cancer interrelation. Creat Surg Oncol. 2017;7(4):32-7.
14. Kahramanca Ş, Anuk T, Ali CY, et al. Blood group characteristics in colorectal cancers. Turk J Colorectal Dis. 2018;28(2):76-79
15. Urun Y, Ozdemir NY, Utkan G, et al. ABO and Rh blood groups and risk of colorectal adenocarcinoma. Asian Pac J Cancer Prev. 2012;13(12):6097-100.
16. Khalili H, Wolpin BM, Huang ES, et al. ABO blood group and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(5):1017-20.
Files
IssueVol 17, No 4 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijhoscr.v17i4.13920
Keywords
Acute promyelocytic leukemia (APL); Hepatotoxicity; Polymorphism
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Joneidi Z, Mortazavi Y, Chahardouli B, Rostami S, Vaezi M, Nabipour M, Biglari A, Ghavamzadeh A. No Association of AS3MT Gene Polymorphisms with Susceptibility to Hepatotoxicity in APL Patients Treated with AS2O3: A Single-Center Study. Int J Hematol Oncol Stem Cell Res. 2023;17(4):281-290.